Smarter GLP-1 care,
built to taper
Targeted prescribing. Lower doses. Real outcomes that last.
Most GLP-1 programs are built to escalate
The typical model is simple: get a prescription, escalate to max dose, stay there forever. With minimal support on the side.
Excessive dose escalation
Faster isn’t better. High doses increase cost and side effects without necessarily improving outcomes.
No behavioral foundation
Medication without coaching leads to drop-off, plateaus, and dependency.
No plan to taper
Most vendors have no off-ramp, which means that members stay on the drug indefinitely.
Behavior is the foundation. Medication is the amplifier.
We don’t offer GLP-1s as a standalone benefit. Every prescription is delivered within a structured, coach-led care model because behavior change is what makes outcomes stick.
We call it treat-to-target: conservative, coordinated, and designed to taper.
How our GLP-1 model differs
1. Medication never stands alone
Embla is not a medication-first model. GLP-1s are only available as part of the full program — where coaching, clinical care, and behavior change run in parallel from day one.
Members start 1:1 coaching immediately. A personalized behavior plan is in place before the first dose. There is no version of Embla where medication runs solo — coaching isn't an add-on. It's what makes outcomes sustainable and tapering possible.
2. We titrate slowly — and only when needed
We don't race to the maximum dose. Dose decisions are guided by weight loss pace, hunger levels, and tolerability — not a default escalation schedule.
Median dose at week 64: 1.08 mg/week. (semaglutide). 71.2% of members stay at or below 1 mg. Escalation only happens when it's clinically necessary, and always in coordination with the member's coach.
3. Coaches and clinicians work as one team
Because we deliver coaching, prescribing, and monitoring under one roof, care doesn't fragment.
Our Emblazer clinical platform gives every provider full visibility into weight trends, engagement patterns, satiety cues, and side effects — so medication and coaching decisions are always informed by the same picture.
4. Tapering is the plan — not the exception
Most GLP-1 programs aren't built to taper. Embla is built around it.
From enrollment, we're already planning the exit ramp.
Tapering begins when members reach target weight, demonstrate sustained behavior change, and are stable at a lower dose. 78.5% successfully taper or stop medication — with no average weight regain.
Results that speak for themselves
Our peer-reviewed, DOM-published TRIM (treat-to-target) study — one of the largest real-world GLP-1 studies to date — validated our model:
How it works
Flexible delivery — always coaching-led
Embla never offers medication alone. We integrate prescribing, coaching, and care protocols into one seamless experience.
Fully managed
We provide coaching, medication, clinical oversight, tapering, and real-time reporting.
Shared delivery
Your clinicians prescribe. We power the behavioral engine: coaching, coordination, and protocol enforcement.
Want to see our GLP-1 model in action?
We’ll walk you through exactly how Embla delivers lower-dose, behavior-led, fully managed GLP-1 care — and why it outperforms traditional models.